George Fareed, MD
General Practice · Calexico, CANPI 1720074313
Payments from drug & device makers
Across 357 payments — averaging $20.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$1K
- Johnson & Johnson$1K
- Janssen Products, LP$676
- Gilead$549
- AstraZeneca$410
- Novo Nordisk$395
- plus $3K from 38 others
What the payments were for
- Speaking & faculty fees$260%
- Food & beverage$6,69591%
- Education$4005%
- Other$2684%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 63 | $1,327 |
| Johnson & Johnson(2 entities) | 85 | $1,132 |
| Janssen Products, LP | 9 | $676 |
| Gilead | 51 | $549 |
| AstraZeneca | 11 | $410 |
| Novo Nordisk | 11 | $395 |
| Merck | 20 | $337 |
| Smith+Nephew | 20 | $284 |
| Integra Lifesciences Corporation | 3 | $268 |
| Corcept Therapeutics | 10 | $205 |
| AbbVie(2 entities) | 9 | $165 |
| Supernus Pharmaceuticals, Inc. | 2 | $163 |
| Medtronic | 1 | $137 |
| Amgen | 7 | $109 |
| Novartis | 5 | $102 |
| Amarin Pharma, Inc. | 4 | $74 |
| Xeris Pharmaceuticals, Inc. | 3 | $72 |
| Shield Therapeutics Inc | 2 | $68 |
| Dexcom, Inc. | 3 | $67 |
| Nevro Corp. | 1 | $66 |
| Globus Medical | 1 | $65 |
| Lilly USA, LLC | 3 | $62 |
| Teva Pharmaceuticals USA, Inc. | 2 | $57 |
| GSK | 3 | $56 |
| Bsn Medical Inc | 2 | $47 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $43 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
| Misonix Inc | 3 | $41 |
| Exact Sciences | 1 | $34 |
| Boston Scientific | 1 | $33 |
| Cequr Corporation | 1 | $32 |
| Convatec Inc. | 1 | $31 |
| Pfizer | 2 | $31 |
| Daiichi Sankyo Inc. | 2 | $28 |
| Sanofi-aventis U.S. LLC | 2 | $28 |
| Organogenesis Inc. | 1 | $26 |
| Abbott | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $19 |
| Myovant Sciences Inc. | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Bayer | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
| Intuitive Surgical | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$259
- TROKENDI XR$159
- Minimed 670G System$137
- Symtuza$125
- APRETUDE$125
- DOVATO$125
- CYTAL$122
- Ozempic$100
How this compares
$7,389 in reported general payments places this provider in the 95th percentile of 12,963 general practice providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 152 | $740,955 |
| CabenuvaCabotegravir/Rilpivirine | 51 | $343,603 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 72 | $274,668 |
| DovatoDolutegravir Sodium/Lamivudine | 62 | $180,527 |
| EliquisApixaban | 306 | $162,844 |
| FarxigaDapagliflozin Propanediol | 104 | $111,110 |
| OzempicSemaglutide | 92 | $103,805 |
| JardianceEmpagliflozin | 107 | $99,924 |
| XareltoRivaroxaban | 109 | $78,764 |
| TrulicityDulaglutide | 76 | $73,050 |
| RybelsusSemaglutide | 45 | $57,724 |
| EntrestoSacubitril/Valsartan | 93 | $50,988 |
| JulucaDolutegravir/Rilpivirine | 16 | $50,353 |
| JanuviaSitagliptin Phosphate | 51 | $44,301 |
| XifaxanRifaximin | 27 | $41,810 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Janssen Products, LPSymtuza | $676 | $740,955152 claims |
| Viiv Healthcare CompanyCabenuva, Dovato, Juluca, Tivicay | $1,327 | $598,399140 claims |
| GileadBiktarvy, Vemlidy | $549 | $289,33083 claims |
| PfizerEliquis | $31 | $162,844306 claims |
| Novo NordiskOzempic, Rybelsus | $395 | $161,528137 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $15 | $151,883182 claims |
| AstraZenecaFarxiga | $410 | $111,110104 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $62 | $98,16996 claims |
| MerckJanuvia, Delstrigo, Janumet | $337 | $97,55486 claims |
| Johnson & JohnsonXarelto | $1,132 | $78,764109 claims |
| NovartisEntresto | $102 | $50,98893 claims |
| AbbVieLinzess, Creon, Restasis | $165 | $42,11959 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 12,963 general practice providers in California.
Other general practice in Calexico
- Hessam AazamiCanoga Park$88.4M
- Frederic MollRedwood City$5.7M
- Nathan LiLancaster$5.2M
- Milton McCollSan Jose$4.9M
- Bruce TorkanLos Angeles$3.8M
- Daniel JohnsonPalm Desert$1.5M
- Bradley ChingUpland$1.4M
- Jared AdamsSan Francisco$862K
- Marina GoldGlendale$784K
- Eric BrassTorrance$755K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.